Sapience Therapeutics Unveils Promising Data from Lucicebtide Phase 2 Trial at ASCO 2025#United_States#Chicago#Glioblastoma#Sapience_Therapeutics#Lucicebtide
Sapience Therapeutics Unveils Promising Data from Lucicebtide Phase 2 Trial at ASCO 2025
Sapience Therapeutics shares positive updates on Lucicebtide during the 2025 ASCO Annual Meeting, showcasing its potential in glioblastoma treatment.
third-news.com
June 2, 2025 at 12:09 PM
Sapience Therapeutics Unveils Promising Data from Lucicebtide Phase 2 Trial at ASCO 2025#United_States#Chicago#Glioblastoma#Sapience_Therapeutics#Lucicebtide
Sapience Therapeutics to Present Lucicebtide Phase 2 Results at ASCO 2025#USA#Glioblastoma#Sapience_Therapeutics#Tarrytown#Lucicebtide
Sapience Therapeutics to Present Lucicebtide Phase 2 Results at ASCO 2025
Sapience Therapeutics will showcase Phase 2 trial results for lucicebtide at the ASCO 2025. Learn about this innovative therapy targeting glioblastoma.
third-news.com
May 1, 2025 at 12:11 PM
Sapience Therapeutics to Present Lucicebtide Phase 2 Results at ASCO 2025#USA#Glioblastoma#Sapience_Therapeutics#Tarrytown#Lucicebtide
Sapience Therapeutics Unveils Innovative Cancer Research at AACR Annual Meeting#United_States#Chicago#Sapience_Therapeutics#ST316#Lucicebtide
Sapience Therapeutics Unveils Innovative Cancer Research at AACR Annual Meeting
At the AACR Annual Meeting 2025, Sapience Therapeutics will showcase groundbreaking research on peptide therapeutics aimed at combating cancer.
third-news.com
March 26, 2025 at 12:16 PM
Sapience Therapeutics Unveils Innovative Cancer Research at AACR Annual Meeting#United_States#Chicago#Sapience_Therapeutics#ST316#Lucicebtide
Innovative Cancer Treatment ST316 Shows Promise in Phase 1 Trials at ASCO 2025#USA#Cancer_Treatment#Sapience_Therapeutics#ST316#Tarrytown,_NY
Innovative Cancer Treatment ST316 Shows Promise in Phase 1 Trials at ASCO 2025
Sapience Therapeutics presents encouraging Phase 1 data on ST316, a peptide therapy targeting advanced colorectal cancer, at ASCO 2025. Insights include safety and biomarker findings.
third-news.com
January 27, 2025 at 1:28 PM
Innovative Cancer Treatment ST316 Shows Promise in Phase 1 Trials at ASCO 2025#USA#Cancer_Treatment#Sapience_Therapeutics#ST316#Tarrytown,_NY
Sapience Therapeutics' ST316 Gains Orphan Drug Designation for Rare Genetic Condition FAP#United_States#FDA#Sapience_Therapeutics#Tarrytown#ST316
Sapience Therapeutics' ST316 Gains Orphan Drug Designation for Rare Genetic Condition FAP
Sapience Therapeutics has secured FDA Orphan Drug Designation for ST316, marking a significant step towards treating Familial Adenomatous Polyposis.
third-news.com
December 19, 2024 at 1:20 PM
Sapience Therapeutics' ST316 Gains Orphan Drug Designation for Rare Genetic Condition FAP#United_States#FDA#Sapience_Therapeutics#Tarrytown#ST316
Sapience Therapeutics Expands Leadership Team with New Appointments to Drive Oncology Programs#United_States#Sapience_Therapeutics#Pamela_Esposito#Augustine_Bourne#Tarrytown
Sapience Therapeutics Expands Leadership Team with New Appointments to Drive Oncology Programs
Sapience Therapeutics strengthens its leadership with the appointment of esteemed executives to enhance its oncology development strategy, focusing on innovative peptide therapeutics.
third-news.com
December 5, 2024 at 1:48 PM
Sapience Therapeutics Expands Leadership Team with New Appointments to Drive Oncology Programs#United_States#Sapience_Therapeutics#Pamela_Esposito#Augustine_Bourne#Tarrytown